Q2 Earnings Forecast for IRWD Issued By Zacks Research

Key Points

• Zacks Research estimates that Ironwood Pharmaceuticals will report earnings of $0.01 per share for Q2 2027, while the current consensus for the full-year is $0.10 per share.
• Ironwood Pharmaceuticals reported $0.14 EPS for the last quarter, surpassing expectations by $0.16 and generating revenues of $85.24 million, exceeding analyst estimates.
• Wall Street Zen upgraded Ironwood Pharmaceuticals' rating from "hold" to a "strong-buy", though the average rating remains a "Hold" with a price target of $4.94.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities research analysts at Zacks Research issued their Q2 2027 earnings per share estimates for shares of Ironwood Pharmaceuticals in a note issued to investors on Monday, September 8th. Zacks Research analyst Team expects that the biotechnology company will post earnings of $0.01 per share for the quarter. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%.The firm had revenue of $85.24 million during the quarter, compared to analyst estimates of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS.

Separately, Wall Street Zen raised shares of Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. One equities research analyst has rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $4.94.

Ironwood Pharmaceuticals Stock Down 2.2%

NASDAQ:IRWD opened at $1.13 on Tuesday. Ironwood Pharmaceuticals has a 52 week low of $0.53 and a 52 week high of $5.13. The firm has a 50 day moving average of $0.94 and a 200 day moving average of $0.98. The stock has a market capitalization of $183.55 million, a price-to-earnings ratio of -22.60 and a beta of 0.32.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Wyoming raised its holdings in shares of Ironwood Pharmaceuticals by 249.9% in the second quarter. State of Wyoming now owns 205,644 shares of the biotechnology company's stock worth $147,000 after buying an additional 146,869 shares during the last quarter. Captrust Financial Advisors purchased a new stake in Ironwood Pharmaceuticals during the 2nd quarter valued at about $32,000. Tidal Investments LLC purchased a new stake in Ironwood Pharmaceuticals during the 2nd quarter valued at about $222,000. Engineers Gate Manager LP grew its stake in Ironwood Pharmaceuticals by 369.2% during the 2nd quarter. Engineers Gate Manager LP now owns 73,354 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 57,720 shares during the last quarter. Finally, Bridgeway Capital Management LLC grew its stake in Ironwood Pharmaceuticals by 141.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 75,000 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 44,000 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.